jcm-logo

Journal Browser

Journal Browser

Helicobacter pylori-Associated Intestinal Diseases and Beyond

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 25 February 2026 | Viewed by 412

Special Issue Editor


E-Mail Website
Guest Editor
Gastroenterology Unit, Faculty of Medicine and Surgery, University of Salento, 73100 Lecce, Italy
Interests: hepatocellular carcinoma; liver diseases; cirrhosis; liver cirrhosis; metabolic syndrome; insulin resistance; diabetes mellitus; gastrointestinal diseases; hepatobiliary surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Helicobacter pylori has been implicated in the pathogenesis of a number of digestive tract disorders, such as chronic active gastritis, peptic ulceration, gastric cancer, and mucosa-associated lymphoid tissue lymphoma. Disease outcome is dependent on many factors, including bacterial genotype, host physiology and genetics, and environmental factors such as diet. There is active research to explore the complexities of H. pylori infection, seeking to explain why some individuals have asymptomatic infection, whereas others experience clinical disease. Likewise, this Special Issue covers advanced research focused on intestinal disorders, presenting insights into both established and emerging pathogenesis, diagnostics, and treatments. A specific focus will be on personalized medicine and advanced diagnostic tools in intestinal disease. Additionally, artificial intelligence is revolutionizing diagnostics, enabling faster and more accurate disease identification, predictive modeling, and patient monitoring, which are critical for early intervention.

With this Special Issue, we aim for gastroenterologists and researchers to gain access to the latest findings, enabling them to provide innovative and effective patient-centered care.

Dr. Antonio Facciorusso
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • IBD
  • Hp
  • stomach
  • celiac disease
  • diverticulosis
  • diverticulitis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 576 KiB  
Article
Efficacy and Safety of 1 L PEG-ASC Preparation for Colonoscopy in Patients with Inflammatory Bowel Diseases: A Multicenter Observational Study
by Antonio Facciorusso, Elisa Stasi, Armando Dell’Anna, Mattia Brigida, Eyad Gadour, Aymen Almuhaidb, Badr Al-Bawardy, Marcello Maida and Rodolfo Sacco
J. Clin. Med. 2025, 14(14), 5043; https://doi.org/10.3390/jcm14145043 - 16 Jul 2025
Viewed by 343
Abstract
Background/Objectives: The effectiveness of 1 L PEG-ASC preparation in inflammatory bowel disease (IBD) patients is still unclear. The aim of this study was to determine the efficacy and safety of 1 L PEG-ASC in a series of IBD patients. Methods: Data [...] Read more.
Background/Objectives: The effectiveness of 1 L PEG-ASC preparation in inflammatory bowel disease (IBD) patients is still unclear. The aim of this study was to determine the efficacy and safety of 1 L PEG-ASC in a series of IBD patients. Methods: Data from a study conducted on a series of 284 patients collected in three centers between 2020 and 2025 were analyzed. The primary outcome was cleansing success whereas success in the right colon, polyp detection, adverse events, and patient reported outcomes were secondary endpoints. Results: The mean age was 43.28 ± 12.21 years and 170 (59.8%) patients were male. Out of 141 ulcerative colitis (UC) patients, 45 (32%) presented with a Mayo score of 3. The Mean Simple Endoscopic Score Crohn’s Disease (SES-CD) score in CD patients was 7.2 ± 7.04. Overall and right colon cleansing success were reported in 267 patients (94.2%), of which 134 CD (93.9%) and 133 UC (94.6%) patients (p = 0.81). The overall BBPS score was 7.47 ± 1.44, specifically 7.52 ± 1.23 in CD and 7.40 ± 1.62 in UC patients (p = 0.76). Overall, 19 patients (6.7%) were diagnosed with polyps with a mean number of polyps per colonoscopy of 0.08 ± 0.03. The preparation was completely taken by 264 (92.9%) patients, and 247 patients (86.9%) declared their willingness to repeat the bowel preparation. Severe nausea was observed in 1 (0.3%) patient and no other severe adverse events were recorded. Conclusions: The 1 L PEG-ASC preparation is well-tolerated and safe in IBD patients. Full article
(This article belongs to the Special Issue Helicobacter pylori-Associated Intestinal Diseases and Beyond)
Show Figures

Figure 1

Back to TopTop